Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 10/20 | 1.00 |
| ▸ | MAOB | P27338 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 3/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | F3 | P13726 | 2/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH2 | P05091 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 0.86 |
| ▸ | PKM | P14618 | 1/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.86 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.86 |
| ▸ | RELA | Q04206 | 1/20 | 0.86 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.78 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4'-Hydroxychalcone SCHEMBL127606 | 1.00 | CYP1B1 (1.00) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| 4'-Hydroxychalcone SCHEMBL25232573 | 1.00 | CYP1B1 (1.00) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| 4,4'-Dihydroxychalcone SCHEMBL20608175 | 0.96 | CYP1B1 (0.93) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| 4,4'-Dihydroxychalcone SCHEMBL20608174 | 0.96 | CYP1B1 (0.93) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| SCHEMBL17061353 | 0.95 | CYP1B1 (0.90) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| SCHEMBL25285070 | 0.95 | CYP1B1 (0.90) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| SCHEMBL17061354 | 0.95 | CYP1B1 (0.90) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| 4,4'-Dihydroxychalcone SCHEMBL9542070 | 0.94 | KMT2A (0.96) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| 4,4'-Dihydroxychalcone SCHEMBL25282681 | 0.94 | KMT2A (0.96) | CYP1B1MAOBMAPTKMT2AHSPD1 | |
| Chalcone SCHEMBL28414035 | 0.92 | CYP1B1 (0.86) | CYP1B1MAOBMAPTKMT2AHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260096569-A1 | EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES | APEEL TECH INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260002134-A1 | CHOROID PLEXUS ORGANOIDS AND METHODS FOR PRODUCTION THEREOF | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2026-01-01 | — | — | US | claimed |
| US-20250092358-A1 | In Vitro Breeding Systems and Methods in Livestock | ABS GLOBAL, INC. (US) | 2025-03-20 | — | — | US | claimed |
| CN-113631701-B | Choroid plexus organ and method for producing same | 英国研究与创新组织 | 2025-03-14 | — | — | CN | claimed |
| EP-4496476-A1 | GAS PHASE TREATMENT OF PRODUCE | Apeel Technology, Inc. (US) | 2025-01-29 | — | — | EP | claimed |
| CN-118105365-A | Use of a compound in the manufacture of a medicament for preventing or treating idiopathic vomiting in a companion animal | 马斯公司 | 2024-05-31 | — | — | CN | claimed |
| EP-4346395-A1 | IN VITRO BREEDING SYSTEMS AND METHODS IN LIVESTOCK | ABS Global, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117412668-A | Livestock in vitro breeding system and method | ABS全球公司 | 2024-01-16 | — | — | CN | claimed |
| CN-117320559-A | Edible coating with antimicrobial properties | 阿比尔技术公司 | 2023-12-29 | — | — | CN | claimed |
| WO-2023183341-A1 | GAS PHASE TREATMENT OF PRODUCE | APEEL TECHNOLOGY, INC. (US) | 2023-09-28 | — | — | WO | claimed |
| EP-2986136-B1 | COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING | MARS INC (US) | 2020-08-12 | — | — | EP | claimed |
| US-10548935-B2 | Composition and method for preventing, reducing, alleviating or treating idiopathic vomiting | MARS, INCORPORATED (US) | 2020-02-04 | — | — | US | claimed |
| US-20190002886-A1 | SIGNALING CENTERS OF ERYTHROID DIFFERENTIATION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-01-03 | — | — | US | claimed |
| EP-2986136-A1 | COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING | The Iams Company (US) | 2016-02-24 | — | — | EP | claimed |
| CN-105188400-A | Compositions and methods for preventing, reducing, alleviating, or treating idiopathic vomiting | IAMS COMPANY | 2015-12-23 | — | — | CN | claimed |
| US-20140271949-A1 | Composition and Method for Preventing, Reducing, Alleviating or Treating Idiopathic Vomiting | THE IAMS COMPANY (US) | 2014-09-18 | — | — | US | claimed |
| WO-2014143539-A1 | COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING | THE IAMS COMPANY (US) | 2014-09-18 | — | — | WO | claimed |
| US-20030104145-A1 | Chemical adsorbent and liquid crystal alignment layer utilizing the same and liquid crystal display device utilizing the same and methods of manufacturing them | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2003-06-05 | — | — | US | claimed |
| US-6495221-B1 | EXTREMELY THIN AND TRANSPARENT FILM IN NANOMETER ORDER; HYDROCHALCONE DERIVATIVE SUBSTITUTED WITH A ISOCYANATOSILYL GROUP | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2002-12-17 | — | — | US | claimed |
| EP-0962460-A1 | CHEMISORPTIVE SUBSTANCE, ALIGNED LIQUID-CRYSTAL FILM AND LIQUID-CRYSTAL DISPLAY ELEMENT BOTH MADE BY USING THE SAME, AND PROCESSES FOR PRODUCING THESE | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1999-12-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104145-A1 | Chemical adsorbent and liquid crystal alignment layer utilizing the same and liquid crystal display device utilizing the same and methods of manufacturing them | UACA, CRYAA, CUTA | CYP1B1 2725/4885MAOB 2509/4885MAPT 46/4885 |
| US-20260002134-A1 | CHOROID PLEXUS ORGANOIDS AND METHODS FOR PRODUCTION THEREOF | BMP4, WNT3A, BMP1 | CYP1B1 3775/4885MAOB 4449/4885MAPT 1666/4885 |
| US-20190002886-A1 | SIGNALING CENTERS OF ERYTHROID DIFFERENTIATION | EPOR, EBP, HCLS1 | CYP1B1 3228/4885MAOB 3801/4885MAPT 4762/4885 |
| US-20260096569-A1 | EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES | CYP51A1, ERG28, NISCH | CYP1B1 1186/4885MAOB 1312/4885MAPT 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.